BMEA - Biomea Fusion

-

$undefined

N/A

(N/A)

Biomea Fusion NASDAQ:BMEA Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

Location: | Website: www.biomeafusion.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

23.76M

Cash

58.28M

Avg Qtr Burn

-29.97M

Short % of Float

35.31%

Insider Ownership

14.81%

Institutional Own.

61.28%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Update

BMF-219 (icovamenib) Details
Type 1 diabetes

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 2

Initiation

Phase 1

Update

BMF-219 (icovamenib) Details
Acute myeloid leukemia, Acute lymphoblastic leukemia

Failed

Discontinued

BMF-219 (icovamenib) Details
Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma

Failed

Discontinued